NuVasive (NUVA) Misses Q1 EPS by 6c; Reiterates Outlook

NuVasive (NASDAQ: NUVA) reported Q1 EPS of $0.39, $0.06 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $260.5 million versus the consensus estimate of $259.43 million.

The Company reiterated its full-year 2018 guidance, and assumes a full-year benefit of U.S. tax reform, suspension of the medical device tax and the recent acquisition of SafePassage.

For earnings history and earnings-related data on NuVasive (NUVA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• HSBC Upgrades Sembcorp Industries (SCI:SP) to Buy